Beta Bionics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Boston MA United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2016
NCT02971228
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Beta Bionics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

dasiglucagon (2 trials)

Drugs in Phase 2 Trials (2)

glucagon (1 trial)

insulin lispro (humalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 1 (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3